24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
TREXLIEVA 50MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | TREXLIEVA 50MG |
|---|---|
| Composition | Methotrexate Injection IP 50mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
TREXLIEVA 50MG (Methotrexate Injection IP 50mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
TREXLIEVA 50 MG (Methotrexate Injection IP 50 mg) is a prescription medicine containing Methotrexate 50 mg, a widely used antimetabolite and antifolate agent utilized in the treatment of various cancers, autoimmune disorders, and certain severe inflammatory conditions. In oncology, Methotrexate plays a crucial role in controlling the growth and spread of rapidly dividing cancer cells by interfering with DNA synthesis and cell replication.
Methotrexate has been a cornerstone of cancer treatment for decades and is commonly used in hospitals, oncology centers, and specialized healthcare facilities worldwide. The medicine is prescribed for the management of cancers such as Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Breast Cancer, Head and Neck Cancer, Gestational Trophoblastic Disease, and various other malignancies. It may also be used for selected non-cancer medical conditions under specialist supervision.
Cancer cells require folic acid to produce DNA and multiply. TREXLIEVA 50 MG works by inhibiting the enzyme Dihydrofolate Reductase (DHFR), which is essential for folic acid metabolism. By blocking this enzyme, Methotrexate prevents cancer cells from producing the DNA necessary for growth and division, ultimately slowing disease progression and promoting cancer cell death.
TREXLIEVA 50 MG is commonly prescribed for:
The medicine may be administered alone or in combination with other anticancer agents depending on the type of cancer, disease stage, and treatment objectives.
Manufactured under stringent pharmaceutical quality standards, TREXLIEVA 50 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness. The injection should only be administered by qualified healthcare professionals experienced in oncology and chemotherapy treatment.
Patients receiving Methotrexate therapy often require regular blood tests, liver function assessments, kidney function evaluations, and routine clinical monitoring to ensure safe and effective treatment outcomes.
Due to its established efficacy and broad therapeutic applications, TREXLIEVA 50 MG remains an important medicine in modern oncology and specialized medical care.
TREXLIEVA 50 MG (Methotrexate Injection IP 50 mg) is primarily used for the treatment of various cancers and certain medical conditions requiring antimetabolite therapy.
The medicine is widely used in leukemia treatment protocols to help control abnormal white blood cell growth.
Methotrexate may be prescribed as part of comprehensive lymphoma treatment plans.
The medicine may be included in selected chemotherapy regimens for breast cancer management.
Doctors may prescribe Methotrexate to help manage certain cancers affecting the head and neck region.
The medicine is used in the treatment of trophoblastic tumors and related conditions.
Methotrexate is frequently administered alongside other anticancer medicines to improve treatment effectiveness.
The medicine supports comprehensive treatment strategies across multiple cancer types.
Methotrexate belongs to a class of medicines known as Antimetabolites and Antifolate Agents.
TREXLIEVA works by:
This mechanism helps control disease progression and improve treatment outcomes.
Like all chemotherapy medicines, TREXLIEVA 50 MG may cause side effects in some patients. Side effects vary depending on dosage, treatment duration, and individual patient factors.
Patients may experience mild to moderate nausea during treatment.
Episodes of vomiting may occur after administration.
Weakness and tiredness are commonly reported.
Reduced appetite may affect nutritional intake.
Oral ulcers and mouth irritation may develop during therapy.
Digestive disturbances and loose stools may occur.
Temporary hair loss or thinning may occur in some patients.
Some individuals may experience skin-related reactions.
Methotrexate may reduce:
This may increase the risk of infections, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of TREXLIEVA 50 MG (Methotrexate Injection IP 50 mg) should always be determined by a qualified oncologist or healthcare professional.
Different cancers and medical conditions require different treatment schedules.
Dosage is commonly calculated according to body size.
Kidney health significantly influences Methotrexate dosing.
Patients with liver impairment may require special monitoring and dosage adjustments.
Doctors may modify therapy based on effectiveness and side effect management.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid possible drug interactions.
Pregnant women should not receive Methotrexate unless specifically recommended by a healthcare professional because the medicine may cause serious harm to an unborn baby.
Breastfeeding should generally be avoided during treatment unless advised otherwise by a healthcare provider.
It is used for the treatment of various cancers including leukemia, lymphoma, breast cancer, head and neck cancer, and gestational trophoblastic disease.
Methotrexate is an antimetabolite and antifolate medicine that interferes with DNA synthesis and cancer cell growth.
Yes, it is a widely used chemotherapy medicine utilized in several oncology treatment protocols.
Yes, it is frequently included in combination chemotherapy regimens.
Yes, the medicine may lower white blood cells, red blood cells, and platelets, requiring regular monitoring.
Methotrexate is primarily eliminated through the kidneys, making kidney function monitoring essential for patient safety.
Yes, doctors typically recommend blood tests, liver function assessments, kidney evaluations, and routine medical examinations throughout therapy.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology, chemotherapy, and specialized cancer treatment.